{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:38:42Z","timestamp":1792618722017,"version":"4.5.0"},"reference-count":31,"publisher":"MyJove Corporation","issue":"175","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/62811","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T20:01:12Z","timestamp":1632427272000},"source":"Crossref","is-referenced-by-count":2,"title":["&lt;em&gt;In Vivo&lt;\/em&gt; Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells"],"prefix":"10.3791","author":[{"given":"Florian","family":"Stritzke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Poeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heidegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","type":"journal-article","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L. Immunogenic cell death in cancer therapy. Annual Review of Immunology. 31, 51-72 (2013).","journal-title":"Annual Review of Immunology"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"955691","DOI":"10.4161\/21624011.2014.955691","type":"journal-article","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 3 (9), e955691 (2014).","journal-title":"Oncoimmunology"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","type":"journal-article","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. The Journal of Experimental Medicine. 208 (10), 2005-2016 (2011).","journal-title":"The Journal of Experimental Medicine"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","type":"journal-article","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine. 20 (11), 1301-1309 (2014).","journal-title":"Nature Medicine"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","type":"journal-article","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","unstructured":"Fridman, W. H., Pages, F., Sautes-Fridman, C., Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nature reviews. Cancer. 12 (4), 298-306 (2012).","journal-title":"Nature reviews. Cancer"},{"issue":"6832","key":"ref6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","type":"journal-article","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410 (6832), 1107-1111 (2001).","journal-title":"Nature"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","type":"journal-article","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 29 (4), 482-491 (2010).","journal-title":"Oncogene"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","type":"journal-article","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","unstructured":"van Niel, G., D'Angelo, G., Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nature reviews. Molecular Cell Biology. 19 (4), 213-228 (2018).","journal-title":"Nature reviews. Molecular Cell Biology"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-15-2804","type":"journal-article","article-title":"Implications of extracellular vesicle transfer on cellular heterogeneity in cancer: What are the potential clinical ramifications","volume":"76","author":"Zomer","year":"2016","unstructured":"Zomer, A., van Rheenen, J. Implications of extracellular vesicle transfer on cellular heterogeneity in cancer: What are the potential clinical ramifications? Cancer Research. 76 (8), 2071-2075 (2016).","journal-title":"Cancer Research"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI81136","type":"journal-article","article-title":"Exosomes and tumor-mediated immune suppression","volume":"126","author":"Whiteside","year":"2016","unstructured":"Whiteside, T. L. Exosomes and tumor-mediated immune suppression. The Journal of Clinical Investigation. 126 (4), 1216-1223 (2016).","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/85438","type":"journal-article","article-title":"Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming","volume":"7","author":"Wolfers","year":"2001","unstructured":"Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Medicine. 7 (3), 297-303 (2001).","journal-title":"Nature Medicine"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/0008-5472.CAN-07-3163","type":"journal-article","article-title":"Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses","volume":"68","author":"Zeelenberg","year":"2008","unstructured":"Zeelenberg, I. S. et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Research. 68 (4), 1228-1235 (2008).","journal-title":"Cancer Research"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-17-0581","type":"journal-article","article-title":"Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs","volume":"6","author":"Diamond","year":"2018","unstructured":"Diamond, J. M. et al. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunology Research. 6 (8), 910-920 (2018).","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4049\/jimmunol.1601694","type":"journal-article","article-title":"DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity","volume":"198","author":"Kitai","year":"2017","unstructured":"Kitai, Y. et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. Journal of Immunology. 198 (4), 1649-1659 (2017).","journal-title":"Journal of Immunology"},{"issue":"39","key":"ref15","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1126\/sciimmunol.aau8943","type":"journal-article","article-title":"RIG-I activation is critical for responsiveness to checkpoint blockade","volume":"4","author":"Heidegger","year":"2019","unstructured":"Heidegger, S. et al. RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology. 4 (39), eaau8943 (2019).","journal-title":"Science Immunology"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.celrep.2019.09.065","type":"journal-article","article-title":"Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity","volume":"29","author":"Schadt","year":"2019","unstructured":"Schadt, L. et al. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Reports. 29 (5), 1236-1248 e1237 (2019).","journal-title":"Cell Reports"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000940","type":"journal-article","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","unstructured":"Cheng, Y. et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. Journal for Immunotherapy of Cancer. 8 (2) (2020).","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471142735.ima03bs111","type":"journal-article","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","unstructured":"Strober, W. Trypan blue exclusion test of cell viability. Current Protocols in Immunology. 111, A3 B 1-A3 B 3 (2015).","journal-title":"Current Protocols in Immunology"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-017-0160-y","type":"journal-article","article-title":"Preservation and storage stability of extracellular vesicles for therapeutic applications","volume":"20","author":"Jeyaram","year":"2017","unstructured":"Jeyaram, A., Jay, S. M. Preservation and storage stability of extracellular vesicles for therapeutic applications. The AAPS Journal. 20 (1), 1 (2017).","journal-title":"The AAPS Journal"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","type":"journal-article","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Thery","year":"2018","unstructured":"Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles. 7 (1), 1535750 (2018).","journal-title":"Journal of Extracellular Vesicles"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"1344087","DOI":"10.1080\/20013078.2017.1344087","type":"journal-article","article-title":"Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study","volume":"6","author":"Vestad","year":"2017","unstructured":"Vestad, B. et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. Journal of Extracellular Vesicles. 6 (1), 1344087 (2017).","journal-title":"Journal of Extracellular Vesicles"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1038\/s41598-017-11249-2","type":"journal-article","article-title":"A bead-assisted flow cytometry method for the semi-quantitative analysis of Extracellular Vesicles","volume":"7","author":"Suarez","year":"2017","unstructured":"Suarez, H. et al. A bead-assisted flow cytometry method for the semi-quantitative analysis of Extracellular Vesicles. Scientific Reports. 7 (1), 11271 (2017).","journal-title":"Scientific Reports"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v2i0.21494","type":"journal-article","article-title":"Cryo-electron microscopy of extracellular vesicles in fresh plasma","volume":"2","author":"Yuana","year":"2013","unstructured":"Yuana, Y. et al. Cryo-electron microscopy of extracellular vesicles in fresh plasma. Journal of Extracellular Vesicles. 2 (2013).","journal-title":"Journal of Extracellular Vesicles"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/1521-4141(200206)32:6<1567::AID-IMMU1567>3.0.CO;2-P","type":"journal-article","article-title":"Defective generation but normal maintenance of memory T cells in old mice","volume":"32","author":"Kapasi","year":"2002","unstructured":"Kapasi, Z. F., Murali-Krishna, K., McRae, M. L., Ahmed, R. Defective generation but normal maintenance of memory T cells in old mice. European Journal of Immunology. 32 (6), 1567-1573 (2002).","journal-title":"European Journal of Immunology"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.185.3.453","type":"journal-article","article-title":"Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma","volume":"185","author":"Bloom","year":"1997","unstructured":"Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. The Journal of Experimental Medicine. 185 (3), 453-459 (1997).","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41598-019-41800-2","type":"journal-article","article-title":"Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications","volume":"9","author":"Patel","year":"2019","unstructured":"Patel, G. K. et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Scientific Reports. 9 (1), 5335 (2019).","journal-title":"Scientific Reports"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.4049\/jimmunol.159.6.2549","type":"journal-article","article-title":"CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation","volume":"159","author":"DeGrendele","year":"1997","unstructured":"DeGrendele, H. C., Kosfiszer, M., Estess, P., Siegelman, M. H. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. The Journal of Immunology. 159 (6), 2549-2553 (1997).","journal-title":"The Journal of Immunology"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"22530","DOI":"10.1371\/journal.pone.0022560","type":"journal-article","article-title":"The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes","volume":"6","author":"Yang","year":"2011","unstructured":"Yang, S., Liu, F., Wang, Q. J., Rosenberg, S. A., Morgan, R. A. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One. 6 (7), e22560 (2011).","journal-title":"PLoS One"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"1570779","DOI":"10.1080\/2162402X.2019.1570779","type":"journal-article","article-title":"Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines","volume":"8","author":"Bek","year":"2019","unstructured":"Bek, S. et al. Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines. Oncoimmunology. 8 (4), e1570779 (2019).","journal-title":"Oncoimmunology"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cell.2017.06.031","type":"journal-article","article-title":"Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer","volume":"170","author":"Nabet","year":"2017","unstructured":"Nabet, B. Y. et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 170 (2), 352-366 e313 (2017).","journal-title":"Cell"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI87316","type":"journal-article","article-title":"Extracellular vesicles: masters of intercellular communication and potential clinical interventions","volume":"126","author":"Pitt","year":"2016","unstructured":"Pitt, J. M., Kroemer, G., Zitvogel, L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. The Journal of Clinical Investigation. 126 (4), 1139-1143 (2016).","journal-title":"The Journal of Clinical Investigation"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/62811\/in-vivo-immunogenicity-screening-tumor-derived-extracellular-vesicles","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:55:28Z","timestamp":1792616128000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/62811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":31,"journal-issue":{"issue":"175","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3791\/62811","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]}}}